Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-035 in cardiac surgery-associated kidney injury
NCT06475274Phase 2Completed
- Sponsor
- Guard Therapeutics
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of RMC-035 in acute kidney injury (AKI), sponsored by Guard Therapeutics. Started Aug 2024; status: completed.
02
Drugs
RMC-035
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06475274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475274.